Posted in Ankylosing spondylitis, Arthritis Drugs, Psoriatic Arthritis, Research, Treatments • Tags: Abbott, adalimumab, adalimumab therapy, ankylosing spondylitis (AS), anti-tumour necrosis factor (anti-TNF), anti-tumour necrosis factor (anti-TNF) therapies, Etanercept, Humira, infliximab, psoriatic arthritis (PsA), rheumatoid arthritis (RA)
According to results of research presented today at EULAR 2008 (the Annual European Congress of Rheumatology in Paris, France), adalimumab therapy is effective and well-tolerated in ankylosing spondylitis (AS), rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients with a previously inadequate response to anti-tumour necrosis factor (anti-TNF) therapies etanercept and infliximab.
This positive response to adalimumab was greatest for patients who had been intolerant of their anti-TNF therapies, or had lost their initial responses, compared with those who had had no response to prior anti-TNF therapies at all.
More →
Share This
Posted on June 14, 2008 by Gloria Gamat • There are 1 lonesome comment
Posted in Arthritis Drugs, News, Rheumatoid Arthritis, Treatments • Tags: Abbott, Humira, Japanese Ministry of Health, Labour and Welfare, Rheumatoid Arthritis
First it was Roche’s Actimra, now it is Abbott’s Humira that’s been approved in Japan.
The Japanese Ministry of Health, Labour and Welfare has approved Humira for the treatment of rheumatoid arthritis (RA) in patients with inadequate response to conventional therapy.
“The approval of HUMIRA in Japan is a significant milestone for Abbott,” said Glenn Warner, vice president, Pharmaceuticals, Japan, Abbott. “This approval is both good news for Japanese patients and a significant step forward for Abbott in Japan.”
More →
Share This
Posted on April 21, 2008 by Gloria Gamat • There are no comments, hop to it!
I would like the patients to understand their condition better in order to help them discern what is best for their life with arthritis in conjunction to what their doctors are telling them! .. 
